Tag:
Stimuvax
Latest Headlines
Latest Headlines
UPDATED: Merck KGaA bolsters MS pipeline in $20M pact with Ono
If at first you don't succeed with a blockbuster drug, try, try again. Merck KGaA 's Serono division has worked out a pair of new deals that will bring its R&D division in league with the
Merck KGaA's pancreatic cancer vaccine ready for testing
In the quest for a cancer vaccine, Merck KGaA is again stepping into the ring. Vaximm Holding AG, the company's joint venture with a Switzerland's BB Biotech Ventures III, will start testing a
Merck KGaA gets green light on lung cancer vax trials
Merck KGaA got the green light from the FDA to restart its late-stage lung cancer program for its therapeutic vaccine Stimuvax, which had been halted after a patient in a multiple myeloma trial
Merck KGaA gets green light on lung cancer vax program
Merck KGaA got the green light from the FDA to restart its late-stage lung cancer program for its therapeutic vaccine Stimuvax, which had been halted after a patient in a multiple myeloma trial
Merck KGaA: Millipore buy 'worth every euro'
Merck KGaA's $6 billion purchase of Massachusetts-based biotechnology equipment supplier Millipore is "worth every euro," CEO Karl-Ludwig Kley told shareholders at his company's annual general
Researchers see cancer vaccine revolution on the horizon
There are already several cancer vaccine drugs nearing FDA approval. Dendreon's prostate cancer vaccine Provenge is awaiting the agency's OK, and Merck KGaA's Stimuvax is in trials for multiple
Merck KGaA puts Stimuvax trial on hold after encephalitis strikes
A patient enrolled in the mid-stage trial of Merck KGaA's cancer vaccine Stimuvax contracted encephalitis, forcing researchers to suspend dosing for multiple myeloma as they evaluate the safety
Soaring cancer market spurs blockbuster vax studies
Germany's Merck KGaA is barreling ahead with ambitious clinical trial plans for its cancer vaccine Stimuvax, convinced that it has a potential blockbuster drug on its hands. The pharma company is
Merck KGaA to test Stimuvax in breast cancer trial
Germany's Merck KGaA has launched a late-stage trial of the therapeutic vaccine Stimuvax in patients with breast cancer. Already in a Phase III study for non-small cell lung cancer, Merck is out to
